Advertisement

Fifty years of research on antithrombotic therapy: Achievements and disappointments

  • Jack Hirsh
    Affiliations
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Search for articles by this author
  • John W Eikelboom
    Affiliations
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

    Population Health Research Institute, Hamilton, Ontario, Canada
    Search for articles by this author
  • Noel C Chan
    Correspondence
    Corresponding author at: Thrombosis & Atherosclerosis Research Institute, 237 Barton Street East, Hamilton, ON L8L 2×2, Canada.
    Affiliations
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

    Population Health Research Institute, Hamilton, Ontario, Canada
    Search for articles by this author
Published:October 31, 2019DOI:https://doi.org/10.1016/j.ejim.2019.10.023

      Abstract

      The achievements with antithrombotic therapy over the past 50 years have been monumental and the disappointments relatively few. In this review, we will discuss, chronologically, the major developments of the two recognized classes of antithrombotics - anticoagulants and antiplatelet agents.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wardrop D
        • Keeling D
        The story of the discovery of heparin and warfarin.
        Br J Haematol. 2008; 141: 757-763
        • Link KP
        The discovery of dicumarol and its sequels.
        Circulation. 1959; 19: 97-107
        • Weiss H.J.
        • Aledort L.M.
        Impaired platelet-connective-tissue reaction in man after aspirin ingestion.
        Lancet. 1967; 2: 495-497
        • Evans G
        • Packham MA
        • Nishizawa EE
        • Mustard JF
        • Murphy EA
        The effect of acetylsalicyclic acid on platelet function.
        J Exp Med. 1968; 128: 877-894
        • Hirsh J
        • Warkentin TE
        • Shaughnessy SG
        • et al.
        Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
        Chest. 2001; 119: 64S-94S
        • Raschke R.
        • Hirsh J.
        • Guidry J.R.
        Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin.
        Ann Intern Med. 2003; 138: 720-723
        • Hirsh J.
        Optimal intensity and monitoring warfarin.
        Am J Cardiol. 1995; 75: 39b-42b
        • Hirsh J.
        Solving the mystery of excessive warfarin-induced bleeding: a personal historical perspective.
        Thromb Haemost. 2014; 112: 853-856
        • Basu D.
        • Gallus A.
        • Hirsh J.
        • Cade J.
        A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.
        N Engl J Med. 1972; 287: 324-327
        • Hirsh J.
        Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin.
        Adv Exp Med Biol. 1992; 313: 283-295
        • Sackett D.L.
        Clinical epidemiology. what, who, and whither.
        J Clin Epidemiol. 2002; 55: 1161-1166
        • Barritt D.W.
        • Jordan S.C.
        Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.
        Lancet. 1960; 1: 1309-1312
      1. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial.
        Lancet. 1975; 2: 45-51
        • Kakkar V.V.
        • Corrigan T.P.
        • Fossard D.P.
        • Sutherland I.
        • Thirwell J.
        Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial.
        Lancet. 1977; 1: 567-569
        • Hull R.
        • Delmore T.
        • Genton E.
        • et al.
        Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
        N Engl J Med. 1979; 301: 855-858
        • Hull R.D.
        • Raskob G.E.
        • Hirsh J.
        • et al.
        Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
        N Engl J Med. 1986; 315: 1109-1114
        • Hull R.D.
        • Raskob G.E.
        • Brant R.F.
        • Pineo G.F.
        • Valentine K.A.
        Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
        Arch Intern Med. 1997; 157: 2562-2568
        • Levine M.N.
        • Hirsh J.
        • Gent M.
        • et al.
        A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
        Arch Intern Med. 1994; 154: 49-56
        • Salzman EW
        • Deykin D
        • Shapiro RM
        • Rosenberg R
        Management of heparin therapy: controlled prospective trial.
        N Engl J Med. 1975; 292: 1046-1050
        • Glazier R.L.
        • Crowell E.B.
        Randomized prospective trial of continuous vs intermittent heparin therapy.
        Jama. 1976; 236: 1365-1367
        • Wilson 3rd, J.E.
        • Bynum L.J.
        • Parkey R.W.
        Heparin therapy in venous thromboembolism.
        Am J Med. 1981; 70: 808-816
      2. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research committee of the British thoracic society.
        Lancet. 1992; 340: 873-876
        • Schulman S.
        • Rhedin A.S.
        • Lindmarker P.
        • et al.
        A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. duration of anticoagulation trial study group.
        N Engl J Med. 1995; 332: 1661-1665
        • Pinede L
        • Ninet J
        • Duhaut P
        • et al.
        Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.
        Circulation. 2001; 103: 2453-2460
        • Campbell I.A.
        • Bentley D.P.
        • Prescott R.J.
        • Routledge P.A.
        • Shetty H.G.M.
        • Williamson I.J.
        Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.
        BMJ (Clinical research ed). 2007; 334 (674-674)
      3. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.
        N Engl J Med. 1982; 307: 1676-1681
      4. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement.
        Lancet. 1988; 1: 1242-1245
        • Hull R.
        • Hirsh J.
        • Jay R.
        • et al.
        Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.
        N Engl J Med. 1982; 307: 1676-1681
        • Hull R.
        • Delmore T.
        • Carter C.
        • et al.
        Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
        N Engl J Med. 1982; 306: 189-194
      5. A national standard for anticoagulant therapy. The Manchester comparative reagent.
        Lancet. 1967; 1: 491-493
        • Hart R.G.
        • Pearce L.A.
        • Aguilar M.I.
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146: 857-867
        • Hirsh J
        Low-molecular-weight heparin.
        Circulation. 1998; 98: 1575-1582
        • Koopman M.M.
        • Prandoni P.
        • Piovella F.
        • et al.
        Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
        N Engl J Med. 1996; 334: 682-687
        • Levine M.
        • Gent M.
        • Hirsh J.
        • et al.
        A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
        N Engl J Med. 1996; 334: 677-681
        • Oler A
        • Whooley MA
        • Oler J
        • Grady D
        Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
        JAMA. 1996; 276: 811-815
        • Petersen JL
        • Mahaffey KW
        • Hasselblad V
        • et al.
        Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
        JAMA. 2004; 292: 89-96
        • Silvain J.
        • Beygui F.
        • Barthelemy O.
        • et al.
        Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.
        Bmj. 2012; 344: e553
        • Eikelboom J.W.
        • Anand S.S.
        • Malmberg K.
        • Weitz J.I.
        • Ginsberg J.S.
        • Yusuf S.
        Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
        Lancet. 2000; 355: 1936-1942
        • Rothberg M.B.
        • Celestin C.
        • Fiore L.D.
        • Lawler E.
        • Cook J.R.
        Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.
        Ann Intern Med. 2005; 143: 241-250
        • Okamoto S.
        • Hijikata A.
        • Kikumoto R.
        • et al.
        Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereo-structure of its hydrophobic carboxamide portion.
        Biochem Biophys Res Commun. 1981; 101: 440-446
        • Ikoma H.
        Development of argatroban as an anticoagulant and antithrombin agent in japan.
        Pathophysiol Haemost Thromb. 2002; 32: 23-28
        • Choay J.
        • Petitou M.
        • Lormeau J.C.
        • Sinay P.
        • Casu B.
        • Gatti G.
        Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.
        Biochem Biophys Res Commun. 1983; 116: 492-499
        • Petitou M.
        • Duchaussoy P.
        • Herbert J.M.
        • et al.
        The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
        Semin Thromb Hemost. 2002; 28: 393-402
        • Maraganore J.M.
        • Chao B.
        • Joseph M.L.
        • Jablonski J.
        • Ramachandran K.L.
        Anticoagulant activity of synthetic hirudin peptides.
        J Biol Chem. 1989; 264: 8692-8698
        • Maraganore JM
        • Bourdon P
        • Jablonski J
        • Ramachandran KL
        • Fenton 2nd, JW
        Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.
        Biochemistry. 1990; 29: 7095-7101
        • Coppens M
        • Eikelboom JW
        • Gustafsson D
        • Weitz JI
        • Hirsh J
        Translational success stories.
        Circ. Res. 2012; 111: 920-929
        • Bauer K.A.
        • Hawkins D.W.
        • Peters P.C.
        • et al.
        Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
        Cardiovasc Drug Rev. 2002; 20: 37-52
        • Yusuf S.
        • Mehta S.R.
        • Chrolavicius S.
        • et al.
        Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
        N Engl J Med. 2006; 354: 1464-1476
        • Coussement P.K.
        • Bassand J.P.
        • Convens C.
        • et al.
        A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The pentalyse study.
        Eur Heart J. 2001; 22: 1716-1724
        • Simoons M.L.
        • Bobbink I.W.
        • Boland J.
        • et al.
        A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the pentasaccharide in unstable angina (PENTUA) study.
        J Am Coll Cardiol. 2004; 43: 2183-2190
        • Mehta SR
        • Steg PG
        • Granger CB
        • et al.
        Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: arixtra study in percutaneous coronary intervention: a randomized evaluation (ASPIRE) pilot trial.
        Circulation. 2005; 111: 1390-1397
        • Budaj A.
        • Eikelboom J.W.
        • Mehta S.R.
        • et al.
        Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
        Eur Heart J. 2009; 30: 655-661
        • Eikelboom JW
        • Mehta SR
        • Anand SS
        • Xie C
        • Fox KA
        • Yusuf S
        Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.
        Circulation. 2006; 114: 774-782
        • Connolly S.J.
        Anticoagulant-related bleeding and mortality.
        J Am Coll Cardiol. 2016; 68: 2522-2524
        • Chan NC
        • Weitz JI
        antithrombotic agents.
        Circ Res. 2019; 124: 426-436
        • Gustafsson D.
        • Nystrom J.
        • Carlsson S.
        • et al.
        The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
        Thromb Res. 2001; 101: 171-181
        • Francis C.W.
        • Berkowitz S.D.
        • Comp P.C.
        • et al.
        Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
        N Engl J Med. 2003; 349: 1703-1712
        • Fiessinger JN
        • Huisman MV
        • Davidson BL
        • et al.
        Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
        JAMA. 2005; 293: 681-689
        • Schulman S.
        • Wahlander K.
        • Lundstrom T.
        • Clason S.B.
        • Eriksson H.
        Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
        N Engl J Med. 2003; 349: 1713-1721
      6. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
        Lancet. 2003; 362: 1691-1698
        • Albers GW
        • Diener H-C
        • Frison L
        • et al.
        Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
        JAMA. 2005; 293: 690-698
        • Wallentin L
        • Wilcox RG
        • Weaver WD
        • et al.
        Oral ximelagatran for secondary prophylaxis after myocardial infarction: the esteem randomised controlled trial.
        Lancet. 2003; 362: 789-797
        • Gurewich V
        Ximelagatran—promises and concerns.
        JAMA. 2005; 293: 736-739
        • Chan NC
        • Eikelboom JW
        • Weitz JI
        Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants.
        Circ Res. 2016; 118: 1409-1424
        • Pollack C.V.
        • Reilly P.A.
        • van Ryn J.
        • et al.
        Idarucizumab for dabigatran reversal — full cohort analysis.
        New England Journal of Medicine. 2017; 377: 431-441
        • Connolly SJ
        • Crowther M
        • Eikelboom JW
        • et al.
        Full study report of andexanet alfa for bleeding associated with factor xa inhibitors.
        New Eng J Med. 2019; 380: 1326-1335
        • Levy J.H.
        • Ageno W.
        • Chan N.C.
        • Crowther M.
        • Verhamme P.
        • Weitz J.I.
        When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.
        J Thromb Haemost. 2016; 14: 623-627
        • Eikelboom JW
        • Hirsh J
        • Spencer FA
        • Baglin TP
        • Weitz JI
        Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141 (e89S–e119S)
        • FitzGerald GA
        Dipyridamole.
        New Eng JMed. 1987; 316: 1247-1257
      7. A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
        N Engl J Med. 1978; 299: 53-59
        • Cairns J.A.
        • Gent M.
        • Singer J.
        • et al.
        Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.
        N Engl J Med. 1985; 313: 1369-1375
        • Lewis Jr., H.D.
        • Davis J.W.
        • Archibald D.G.
        • et al.
        Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a veterans administration cooperative study.
        N Engl J Med. 1983; 309: 396-403
      8. RAndomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2.
        Lancet. 1988; 332: 349-360
      9. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet trialists' collaboration.
        Br Med J (Clin Res Ed). 1988; 296: 320-331
        • Zheng SL
        • Roddick AJ
        Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis.
        JAMA. 2019; 321: 277-287
        • Bowman L.
        • Mafham M.
        • Wallendszus K.
        • et al.
        Effects of aspirin for primary prevention in persons with diabetes mellitus.
        N Engl J Med. 2018; 379: 1529-1539
        • Gaziano J.M.
        • Brotons C.
        • Coppolecchia R.
        • et al.
        Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2018; 392: 1036-1046
        • McNeil J.J.
        • Wolfe R.
        • Woods R.L.
        • et al.
        Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.
        N Engl J Med. 2018; 379: 1509-1518
        • Chan NC
        • Weitz JI
        Chapter 59 - antiplatelet drugs in the management of venous thromboembolism, cardioembolism, ventricular assist devices, and pregnancy complications.
        in: Michelson AD Platelets (4th Edition). Academic Press, 2019: 1067-1077
      10. Collaborative overview of randomised trials of antiplatelet therapy–III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. antiplatelet trialists’ collaboration.
        BMJ (Clinical Research Ed). 1994; 308: 235-246
      11. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial.
        Lancet. 2000; 355: 1295-1302
        • Simes J
        • Becattini C
        • Agnelli G
        • et al.
        Aspirin for the prevention of recurrent venous thromboembolism: the inspire collaboration.
        Circulation. 2014; 130: 1062-1071
        • Anderson D.R.
        • Dunbar M.J.
        • Bohm E.R.
        • et al.
        Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
        Ann Intern Med. 2013; 158: 800-806
        • Anderson D.R.
        • Dunbar M.
        • Murnaghan J.
        • et al.
        Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty.
        N Engl J Med. 2018; 378: 699-707
        • Hart RG
        • Halperin JL
        • McBride R
        • Benavente O
        • Man-Son-Hing M
        • Kronmal RA
        Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.
        JAMA Neurol. 2000; 57: 326-332
        • van Walraven C
        • Hart RG
        • Singer DE
        • et al.
        Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
        JAMA. 2002; 288: 2441-2448
        • Connolly S.J.
        • Eikelboom J.
        • Joyner C.
        • et al.
        Apixaban in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 806-817
        • Weitz J.I.
        • Lensing A.W.A.
        • Prins M.H.
        • et al.
        Rivaroxaban or aspirin for extended treatment of venous thromboembolism.
        N Engl J Med. 2017; 376: 1211-1222
        • Schunemann H.J.
        • Cushman M.
        • Burnett A.E.
        • et al.
        American society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.
        Blood Adv. 2018; 2: 3198-3225
        • Chan N.C.
        • Siegal D.
        • Lauw M.N.
        • et al.
        A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal.
        J Thromb Thrombolysis. 2015; 40: 231-239
        • Chan N.C.
        • Stehouwer A.C.
        • Hirsh J.
        • et al.
        Lack of consistency in the relationship between asymptomatic dvt detected by venography and symptomatic VTE in thromboprophylaxis trials.
        Thromb Haemost. 2015; 114: 1049-1057
        • Xu K
        • Chan NC
        • Ibrahim Q
        • et al.
        Reduction in mortality following elective major hip and knee surgery: a systematic review and meta-analysis.
        Thromb Haemost. 2019; 119: 668-674
        • Quinn MJ
        • Fitzgerald DJ
        Ticlopidine and clopidogrel.
        Circulation. 1999; 100: 1667-1672
      12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Gurbel PA
        • Bliden KP
        • Hiatt BL
        • O’Connor CM
        Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
        Circulation. 2003; 107: 2908-2913
        • Serebruany VL
        • Steinhubl SR
        • Berger PB
        • Malinin AI
        • Bhatt DL
        • Topol EJ
        Variability in platelet responsiveness to clopidogrel among 544 individuals.
        J Am Coll Cardiol. 2005; 45: 246-251
        • Chan NC
        • Eikelboom JW
        • Ginsberg JS
        • et al.
        Role of phenotypic and genetic testing in managing clopidogrel therapy.
        Blood. 2014; 124: 689-699
        • Angiolillo DJ
        • Capodanno D
        • Goto S
        Platelet thrombin receptor antagonism and atherothrombosis.
        Eur. Heart J. 2010; 31: 17-28
        • Verstraete M
        Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development.
        Circulation. 2000; 101: e76-e80
        • Coller B.S.
        • Peerschke E.I.
        • Scudder L.E.
        • Sullivan C.A.
        A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.
        J Clin Invest. 1983; 72: 325-338
        • Madan M
        • Berkowitz SD
        • Tcheng JE
        Glycoprotein IIb/IIIa integrin blockade.
        Circulation. 1998; 98: 2629-2635
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • Chrolavicius S.
        • Tognoni G.
        • Fox K.K
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Mehta S.R.
        • Yusuf S.
        • Peters R.J.
        • et al.
        Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
        Lancet. 2001; 358: 527-533
        • Chan N.C.
        • Weitz J.I.
        Antiplatelet therapy in the management of atherothrombosis: recent clinical advances.
        Blood Advances. 2018; 2 (1806-1806)
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • et al.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • et al.
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Amsterdam EA
        • Wenger NK
        • Brindis RG
        • et al.
        2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines.
        Circulation. 2014; 130: e344-e426
      13. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin aspirin reinfarction study (CARS) investigators.
        Lancet. 1997; 350: 389-396
        • Anand SS
        • Yusuf S
        Oral anticoagulants in patients with coronary artery disease.
        J Am Coll Cardiol. 2003; 41: S62-S69
        • Eikelboom J.W.
        • Connolly S.J.
        • Bosch J.
        • et al.
        Rivaroxaban with or without aspirin in stable cardiovascular disease.
        N Engl J Med. 2017; 377: 1319-1330
        • Mega J.L.
        • Braunwald E.
        • Wiviott S.D.
        • et al.
        Rivaroxaban in patients with a recent acute coronary syndrome.
        N Engl J Med. 2012; 366: 9-19
        • Bonaca M.P.
        • Bhatt D.L.
        • Cohen M.
        • et al.
        Long-term use of ticagrelor in patients with prior myocardial infarction.
        N Engl J Med. 2015; 372: 1791-1800
        • van Rein N
        • Heide-Jorgensen U
        • Lijfering WM
        • Dekkers OM
        • Sorensen HT
        • Cannegieter SC
        Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy.
        Circulation. 2019; 139: 775-786
        • Dewilde W.J.
        • Oirbans T.
        • Verheugt F.W.
        • et al.
        Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
        Lancet. 2013; 381: 1107-1115
        • Gibson C.M.
        • Mehran R.
        • Bode C.
        • et al.
        Prevention of bleeding in patients with atrial fibrillation undergoing pci.
        N Engl J Med. 2016; 375: 2423-2434
        • Cannon C.P.
        • Bhatt D.L.
        • Oldgren J.
        • et al.
        Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation.
        N Engl J Med. 2017; 377: 1513-1524
        • Lopes RD
        • Vora AN
        • Liaw D
        • et al.
        An open-Label, 2×2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.
        Am Heart J. 2018; 200: 17-23
        • Vranckx P
        • Lewalter T
        • Valgimigli M
        • et al.
        Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial.
        Am Heart J. 2018; 196: 105-112
        • Eikelboom J.W.
        • Connolly S.J.
        • Brueckmann M.
        • et al.
        Dabigatran versus warfarin in patients with mechanical heart valves.
        N Engl J Med. 2013; 369: 1206-1214
        • Chan NC
        • Weitz JI
        • Eikelboom JW
        Anticoagulation for mechanical heart valves: will oral factor xa inhibitors be effective?.
        Arterioscler Thromb Vasc Biol. 2017; 37: 743-745
        • Hart RG
        • Diener H-C
        • Coutts SB
        • et al.
        Embolic strokes of undetermined source: the case for a new clinical construct.
        Lancet Neurology. 2014; 13: 429-438
        • Hart R.G.
        • Sharma M.
        • Mundl H.
        • et al.
        Rivaroxaban for stroke prevention after embolic stroke of undetermined source.
        N Engl J Med. 2018; 378: 2191-2201
        • Diener H.C.
        • Sacco R.L.
        • Easton J.D.
        • et al.
        Dabigatran for prevention of stroke after embolic stroke of undetermined source.
        N Engl J Med. 2019; 380: 1906-1917
        • Piccini JP
        • Sievert H
        • Patel MR
        Left atrial appendage occlusion: rationale, evidence, devices, and patient selection.
        Eur Heart J. 2016; 38: 869-876
        • Tsai Y-C
        • Phan K
        • Munkholm-Larsen S
        • Tian DH
        • La Meir M
        • Yan TD
        Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis.
        Eur J Cardio-Thorac Surg. 2014; 47: 847-854
        • Whitlock R.
        • Healey J.
        • Vincent J.
        • et al.
        Rationale and design of the left atrial appendage occlusion study (LAAOS) III.
        Ann Cardiothorac Surg. 2014; 3: 45-54
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Ridker PM
        anticytokine agents.
        Circ Res. 2019; 124: 437-450
        • Collins R.
        • Scrimgeour A.
        • Yusuf S.
        • Peto R.
        Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.
        N Engl J Med. 1988; 318: 1162-1173
        • Poller L.
        • Taberner D.A.
        Dosage and control of oral anticoagulants: an international collaborative survey.
        Br J Haematol. 1982; 51: 479-485
        • Boutitie F.
        • Pinede L.
        • Schulman S.
        • et al.
        Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials.
        BMJ. 2011; 342: d3036
        • Schulman S.
        • Kearon C.
        • Kakkar A.K.
        • et al.
        Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
        N Engl J Med. 2009; 361: 2342-2352
        • Bauersachs R.
        • Berkowitz S.D.
        • Brenner B.
        • et al.
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N Engl J Med. 2010; 363: 2499-2510
        • Buller H.R.
        • Prins M.H.
        • Lensin A.W.
        • et al.
        Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
        N Engl J Med. 2012; 366: 1287-1297
        • Agnelli G.
        • Buller H.R.
        • Cohen A.
        • et al.
        Oral apixaban for the treatment of acute venous thromboembolism.
        N Engl J Med. 2013; 369: 799-808
        • Buller H.R.
        • Decousus H.
        • Grosso M.A.
        • et al.
        Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
        N Engl J Med. 2013; 369: 1406-1415
        • Agnelli G.
        • Buller H.R.
        • Cohen A.
        • et al.
        Apixaban for extended treatment of venous thromboembolism.
        N Engl J Med. 2013; 368: 699-708
        • Lassen M.R.
        • Raskob G.E.
        • Gallus A.
        • Pineo G.
        • Chen D.
        • Portman R.J.
        Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
        N Engl J Med. 2009; 361: 594-604
        • Lassen M.R.
        • Raskob G.E.
        • Gallus A.
        • Pineo G.
        • Chen D.
        • Hornick P.
        Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
        Lancet. 2010; 375: 807-815
        • Lassen M.R.
        • Gallus A.
        • Raskob G.E.
        • Pineo G.
        • Chen D.
        • Ramirez L.M.
        Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
        N Engl J Med. 2010; 363: 2487-2498
        • Eriksson B.I.
        • Borris L.C.
        • Friedman R.J.
        • et al.
        Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
        N Engl J Med. 2008; 358: 2765-2775
        • Kakkar A.K.
        • Brenner B.
        • Dahl O.E.
        • et al.
        Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
        Lancet. 2008; 372: 31-39
        • Lassen M.R.
        • Ageno W.
        • Borris L.C.
        • et al.
        Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
        N Engl J Med. 2008; 358: 2776-2786
        • Turpie A.G.
        • Lassen M.R.
        • Davidson B.L.
        • et al.
        Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
        Lancet. 2009; 373: 1673-1680
        • Ginsberg J.S.
        • Davidson B.L.
        • Comp P.C.
        • et al.
        Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
        J Arthroplasty. 2009; 24: 1-9
        • Eriksson B.I.
        • Dahl O.E.
        • Rosencher N.
        • et al.
        Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the re-model randomized trial.
        J Thromb Haemost. 2007; 5: 2178-2185
        • Eriksson B.I.
        • Dahl O.E.
        • Rosencher N.
        • et al.
        Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
        Lancet. 2007; 370: 949-956
        • Eriksson B.I.
        • Dahl O.E.
        • Huo M.H.
        • et al.
        Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). a randomised, double-blind, non-inferiority trial.
        Thromb Haemost. 2011; 105: 721-729
        • Cohen A.T.
        • Harrington R.A.
        • Goldhaber S.Z.
        • et al.
        Extended thromboprophylaxis with betrixaban in acutely ill medical patients.
        N Engl J Med. 2016; 375: 534-544
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104